Literature DB >> 17287348

Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice.

Brian M Wilson1, Charles L Cox.   

Abstract

Fragile X syndrome is a common heritable form of mental retardation in humans. Recent neuroanatomical studies indicate an apparent immature appearance of neurons in fragile X syndrome patients and fragile X mental retardation protein (FMRP)-knockout mice, an animal model of this condition. In this work, we investigated possible alterations in synaptic plasticity in the neocortex of FMRP-knockout mice. Extracellular field potentials were recorded from the deep-layer visual neocortex. Long-term potentiation (LTP) was severely attenuated in brain slices from knockout mice relative to that observed in slices from wild-type mice. Considering that neocortical LTP can involve both NMDA receptor-dependent and -independent mechanisms, we attempted to distinguish the nature of LTP attenuated in the knockout condition. In slices from wild-type mice, LTP was partially attenuated by the NMDA receptor antagonist 3-[(+/-)-2-carboxypiperazin-4-yl]-propyl-1-phosphate (CPP); however, the general metabotropic glutamate receptor (mGluR) antagonist alpha-methyl-4-carboxyphenylglycine (MCPG) strongly attenuated LTP, resulting in a response indistinguishable from that observed in slices from knockout mice. The selective mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) attenuated LTP to a similar degree as did MCPG in wild-type slices, but MPEP did not alter the reduced potentiation in knockout slices. Our results suggest that LTP in layer V visual neocortex depends primarily on mGluR5 activation. Our data also indicate that mGluR5-mediated synaptic plasticity is absent in the neocortex of FMRP-knockout mice. Such an alteration may contribute to the cognitive and learning deficits exhibited in these mice as well as in fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287348      PMCID: PMC1892931          DOI: 10.1073/pnas.0610875104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  Mechanisms underlying long-term potentiation of synaptic transmission.

Authors:  D V Madison; R C Malenka; R A Nicoll
Journal:  Annu Rev Neurosci       Date:  1991       Impact factor: 12.449

Review 2.  Contributions of dendritic spines and perforated synapses to synaptic plasticity.

Authors:  R K Calverley; D G Jones
Journal:  Brain Res Brain Res Rev       Date:  1990 Sep-Dec

3.  Transport of fragile X mental retardation protein via granules in neurites of PC12 cells.

Authors:  Yolanda De Diego Otero; Lies-Anne Severijnen; Gert van Cappellen; Mariëtte Schrier; Ben Oostra; Rob Willemsen
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Epilepsy in fragile X syndrome.

Authors:  Elizabeth Berry-Kravis
Journal:  Dev Med Child Neurol       Date:  2002-11       Impact factor: 5.449

5.  Learning-disabled males with a fragile X CGG expansion in the upper premutation size range.

Authors:  R J Hagerman; L W Staley; R O'Conner; K Lugenbeel; D Nelson; S D McLean; A Taylor
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

6.  Common forms of synaptic plasticity in the hippocampus and neocortex in vitro.

Authors:  A Kirkwood; S M Dudek; J T Gold; C D Aizenman; M F Bear
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

7.  The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.

Authors:  D Devys; Y Lutz; N Rouyer; J P Bellocq; J L Mandel
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

8.  Prevalence of the fragile X syndrome in African-Americans.

Authors:  Dana C Crawford; Kellen L Meadows; James L Newman; Lisa F Taft; Elizabeth Scott; Mary Leslie; Lisa Shubek; Patricia Holmgreen; Marshalyn Yeargin-Allsopp; Coleen Boyle; Stephanie L Sherman
Journal:  Am J Med Genet       Date:  2002-07-01

9.  Contribution of the FMR1 gene mutation to human intellectual dysfunction.

Authors:  A L Reiss; L S Freund; T L Baumgardner; M T Abrams; M B Denckla
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

10.  Modulation of cellular excitability in neocortex: muscarinic receptor and second messenger-mediated actions of acetylcholine.

Authors:  C L Cox; R Metherate; J H Ashe
Journal:  Synapse       Date:  1994-02       Impact factor: 2.562

View more
  64 in total

1.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.

Authors:  Aparna Suvrathan; Charles A Hoeffer; Helen Wong; Eric Klann; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Delayed stabilization of dendritic spines in fragile X mice.

Authors:  Alberto Cruz-Martín; Michelle Crespo; Carlos Portera-Cailliau
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 3.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

Review 4.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

5.  Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain.

Authors:  Andrew M Tan; Omar A Samad; Tanya Z Fischer; Peng Zhao; Anna-Karin Persson; Stephen G Waxman
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

6.  Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.

Authors:  Tao Su; Hong-Xing Fan; Tao Jiang; Wei-Wen Sun; Wei-Yi Den; Mei-Mei Gao; Sheng-Qiang Chen; Qi-Hua Zhao; Yong-Hong Yi
Journal:  Psychopharmacology (Berl)       Date:  2010-12-23       Impact factor: 4.530

7.  Fragile X mental retardation protein (FMRP) and the spinal sensory system.

Authors:  Theodore J Price; Ohannes K Melemedjian
Journal:  Results Probl Cell Differ       Date:  2012

8.  Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile X syndrome.

Authors:  Tao Chen; Jing-Shan Lu; Qian Song; Ming-Gang Liu; Kohei Koga; Giannina Descalzi; Yun-Qing Li; Min Zhuo
Journal:  Neuropsychopharmacology       Date:  2014-02-20       Impact factor: 7.853

Review 9.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

Review 10.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.